Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRM | P19623 | 4/20 | 0.69 |
| ▸ | SMS | P52788 | 2/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.62 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.62 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.62 |
| ▸ | PNMT | P11086 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | AHCY | P23526 | 5/20 | 0.58 |
| ▸ | NADK | O95544 | 1/20 | 0.58 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1770034 | 0.93 | DOT1L (0.68) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL30760710 | 0.83 | SRM (0.71) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL4184440 | 0.81 | DOT1L (0.68) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL996891 | 0.81 | DOT1L (0.68) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL5007882 | 0.80 | SRM (0.67) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL11139574 | 0.80 | EHMT1 (0.71) | DOT1LDNMT3BPRMT7PNMTDNMT1 | |
| SCHEMBL5566482 | 0.78 | SRM (0.63) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL21067650 | 0.77 | DOT1L (0.71) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL11135998 | 0.77 | DOT1L (0.66) | SRMSMSDOT1LDNMT3BPRMT7 | |
| SCHEMBL10665713 | 0.77 | DOT1L (1.00) | SRMDOT1LDNMT3BPRMT7PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735303-A1 | Hair growth compositions and methods | Pilosciences (FR) | 2014-05-28 | — | — | EP | claimed |
| US-20040013691-A1 | Immunotoxin as a therapeutic agent and uses thereof | RESEARCH DEVELOPMENT FOUNDATION | 2004-01-22 | — | — | US | claimed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC | 2018-12-20 | — | — | US | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1667727-B1 | POLYAMINE-METAL CHELATOR CONJUGATES | UNIV FLORIDA (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080096974-A2 | Polyamine-Metal Chelator Conjugates | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20060211773-A1 | Polyamine-metal chelator conjugates | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2006-09-21 | — | — | US | disclosed |
| US-7045550-B2 | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-6949679-B1 | Polyamine transport inhibitors | UNIVERSITE LAVAL (CA) | 2005-09-27 | — | — | US | disclosed |
| US-20040013691-A1 | Immunotoxin as a therapeutic agent and uses thereof | RESEARCH DEVELOPMENT FOUNDATION | 2004-01-22 | — | — | US | disclosed |
| US-20030118539-A1 | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | SRM 1/4885SMS 3/4885DOT1L 2184/4885 |
| US-20060211773-A1 | Polyamine-metal chelator conjugates | SLC40A1, SLC7A1, CATSPER1 | SRM 40/4885SMS 84/4885DOT1L 598/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | SRM 1/4885SMS 3/4885DOT1L 2184/4885 |
| US-20080096974-A2 | Polyamine-Metal Chelator Conjugates | SLC7A1, SLC40A1, SRM | SRM 3/4885SMS 13/4885DOT1L 524/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | SRM 8/4885SMS 25/4885DOT1L 4266/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | SRM 2/4885SMS 13/4885DOT1L 862/4885 |
| US-20180360783-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PMP22, MAG, GMFG | SRM 440/4885SMS 824/4885DOT1L 4058/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | SRM 440/4885SMS 824/4885DOT1L 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.